Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

Ki vehet részt

• Be ≥18 years of age
• Provide written informed consent
• Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation
• Have an onset of symptoms within 4 weeks

Ki nem vehet részt

• Have a history of or a current ocular or periocular malignancy
• A confirmed or highly suspicious infectious uveitis eg, CMV, Herpes simplex, Herpes zoster, syphilis, tuberculosis, lyme disease
• Have a known allergy or sensitivity to the IMP tacrolimus or semifluorinated alkanes (SFA)
• Have a condition or be in a situation (e.g. language barrier, non-cooperative, history of substance abuse) which the Investigator considers that it may put the patient at significant risk, may confound the trial results, or may significantly interfere with the patient's participation in the trial
• Have severe/serious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator
• Have active intermediate or posterior uveitis in the study eye or another documented posterior segment inflammation
• Be a woman who is pregnant, nursing, or planning a pregnancy